Comment Pfizer a gagné la course au vaccin contre Moderna ?
Abstract
In the case of a market launch of a new technology, such as the Covid-19 messenger RNA vaccine, the choice of the right partner to partner with does not meet the same selection criteria as in the case of an existing market. Here, the interest of the ally dominates the interest of the market. BioNTech understood this when it chose Pfizer.